Literature DB >> 2283893

A new injection portal for brachially inserted central venous catheter. A multicenter study.

H Starkhammar1, M Bengtsson, T B Gain, W Galen, L Håkansson, J Hirsch, B Loggie, E S Schuman, J M Sterchi.   

Abstract

Totally implantable portal systems are widely used for long-term central venous access. A new venous portal system inserted via the brachial veins (P.A.S. Port system, Pharmacia Deltec Inc, U.S.A.) was studied in five centres. From January 1988 through May 1989 61 systems were implanted. Fifty-two patients had malignant diseases. Nine cases had non-malignant disorders. The portals were implanted subcutaneously in the fore-arm and catheterization was done percutaneously (46) or by cutdown-technique (15) under local anesthesia. Catheter tip position was controlled by fluoroscopy or x-ray. The basilic vein (49) and the cephalic vein (12) were used. The total follow-up time for all systems was 323 months. Forty-five systems were still in use at the end of the observation period, six were explanted electively at the end of infusion therapy and six systems were still functioning at the time of the patient's death (at a maximum of 14 months after implantation). Temporary armphlebitis was noticed on the first postoperative week in five patients. Two P.A.S. Port systems were explanted due to infection and one because of skin rupture at the wound. One intact system was removed as it was thought to be leaking because of needle displacement. The P.A.S. Port system is easy and safe to implant with a high success rate and a low complication rate. It is well accepted by patients and nurses. The device should be advantageous in patients unsuitable for standard venous portal systems and offers an excellent alternative system for venous access.

Entities:  

Mesh:

Year:  1990        PMID: 2283893     DOI: 10.1007/bf02987107

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  8 in total

1.  Comparison of a totally implantable access device for chemotherapy (Port-A-Cath) and long-term percutaneous catheterization (Broviac).

Authors:  F L Greene; W Moore; G Strickland; J McFarland
Journal:  South Med J       Date:  1988-05       Impact factor: 0.954

2.  How much do arm movements displace cubital central venous catheters?

Authors:  E Kalso; P H Rosenberg; M Vuorialho; K Pietilä
Journal:  Acta Anaesthesiol Scand       Date:  1982-08       Impact factor: 2.105

3.  Totally implanted device for venous access. Experience in tumour patients.

Authors:  H Starkhammar; M Bengtsson
Journal:  Acta Radiol Oncol       Date:  1985 Mar-Apr

4.  Long-term intravenous therapy with peripherally inserted silicone elastomer central venous catheters in patients with malignant diseases.

Authors:  J Bottino; K B McCredie; D H Groschel; M Lawson
Journal:  Cancer       Date:  1979-05       Impact factor: 6.860

5.  Material thrombogenicity in central venous catheterization: a comparison between soft, antebrachial catheters of silicone elastomer and polyurethane.

Authors:  L E Linder; I Curelaru; B Gustavsson; H A Hansson; O Stenqvist; J Wojciechowski
Journal:  JPEN J Parenter Enteral Nutr       Date:  1984 Jul-Aug       Impact factor: 4.016

6.  A totally implanted injection port system for blood sampling and chemotherapy administration.

Authors:  J W Gyves; W D Ensminger; J E Niederhuber; T Dent; S Walker; S Gilbertson; E Cozzi; P Saran
Journal:  JAMA       Date:  1984-05-18       Impact factor: 56.272

7.  Fifty-five patient years' experience with a totally implanted system for intravenous chemotherapy.

Authors:  H Brincker; G Saeter
Journal:  Cancer       Date:  1986-03-15       Impact factor: 6.860

8.  Vascular access options for outpatient cancer therapy.

Authors:  E Schuman; A Brady; G Gross; J Hayes
Journal:  Am J Surg       Date:  1987-05       Impact factor: 2.565

  8 in total
  1 in total

1.  Insertion of long term central venous catheters: time for a new look.

Authors:  A Adam
Journal:  BMJ       Date:  1995-08-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.